A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Aripiprazole Lauroxil (ARISTADA)

First FDA approval2015-10-05
Generic availableNo (brand-only)
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$400.4M in CY2024 Part D spend133K claims · 24K beneficiaries · 329 plans surveyed

Lowest NADAC
$988.06/unit
5 NDCs benchmarked, lowest of all strengths.
Average NADAC
$1002.98
Across all dosage forms in distribution.
Highest NADAC
$1026.91
Range is tight.
Plans with PA
165 / 329
Limited PA friction.

Questions a plan sponsor actually asks.

FAQPage schema9 entries indexed · 4 visible
What is Aripiprazole Lauroxil used for?

Aripiprazole Lauroxil is a this drug class medication tracked in Medicare Part D.

Is there a generic for Aripiprazole Lauroxil?

No. Aripiprazole Lauroxil is brand-only with no generic equivalents currently in market.

How much does my plan pay for Aripiprazole Lauroxil?

Across 329 Part D plans, Aripiprazole Lauroxil averages $1002.98/unit (NADAC). Lowest available: $988.06/unit. Highest in distribution: $1026.91/unit.

Is Aripiprazole Lauroxil on the FDA shortage list?

No. Aripiprazole Lauroxil is not currently on the FDA Drug Shortage Database.

5 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (5 approvals on file) · NADAC unit costs: CMS NADAC weekly file (5 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.